Fig. 6. The miR-30e-5p antagomir (Antago) blocked the effects induced by T-96 in glioma cells.

a Quantity real-time PCR (qRT-PCR) assays were performed to evaluate the expression of miR-30e-5p after treatment of LN-229 and A-172 cells with DMSO or 10 μM T-96 for the indicated time. b The expression of miR-30e-5p after T-96 treatment or T-96 and the miR-30e-5p antagomir treatment for 2 days. DMSO was used as the control. c LN-229 and A-172 cells were treated with DMSO, 10 μM T-96, the miR-30e-5p antagomir, or T-96 and the miR-30e-5p antagomir for 2 days, and the cell viability was evaluated with MTT assays. d LN-229 and A-172 cells were treated with DMSO, the miR-30e-5p antagomir, 10 μM T-96 or T-96 and the miR-30e-5p antagomir for 2 days, and cell cycle was analysed via flow cytometry. e Western blot assays were used to detect the expression of MYBL2, CDK4, CDK6 and cyclin D1 after treatment with DMSO, the miR-30e-5p antagomir, 10 μM T-96, or T-96 and the miR-30e-5p antagomir for 2 days. f Densitometry of Western blot in the panel e. All data were analysed using unpaired Student’s t-tests and are shown as the means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns no significant difference